Latest NewsNov 4, 2024HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200604, a Best-in-Class BTLA Agonist Antibody for the Treatment of Inflammatory and Immunology Diseases All Filter By: Year2024202320222021202020192018201720162015Dec 20, 2021FibroGen Exercises Exclusive License Option for HiFiBiO’s CCR8 ProgramNov 1, 2021HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200301Sep 23, 2021HiFiBiO Therapeutics Contributes to CoVIC-Led Science Publication on SARS-CoV-2 Spike Antibodies Effective Against Variants of ConcernJun 17, 2021FibroGen and HiFiBiO Announce Transformative Partnership to Advance Next-Generation Therapies for Patients with Cancer and Autoimmune DiseaseJun 14, 2021HiFiBiO Therapeutics Closes $75 Million Series D Financing to Accelerate Pipeline with Two Lead Immuno-Oncology Programs and Validate its DIS® Approach in the Clinic< 1 … 5 6 7 8 9 … 17 >
